PURPOSE: The increased risk of breast cancer (BC) among women receiving chest radiotherapy for Hodgkin's lymphoma (HL) is well-established. However, there are no large population-based studies that describe overall survival (OS) and cause-specific survival (CSS) compared with women with first primary BC. METHODS: For 298 HL survivors who developed BC (HL-BC group) and 405,223 women with a first or only BC (BC-1 group), actuarial OS and CSS were compared, accounting for age, BC stage, hormone receptor status, sociodemographic status, radiation for HL, and other variables. All patients were derived from the population-based Surveillance, Epidemiology, and End Results program. RESULTS: OS among patients with HL-BC was significantly inferior that of to patients with BC-1: 15-year OS was 48% versus 69% (P < .0001) for localized BC, and 33% versus 43% (P < .0001) for regional/distant BC. Patients with HL-BC had a significantly increased seven-fold risk (P < .0001) of death from other cancers (ie, not HL or BC) compared with patients with BC-1. Mortality from heart disease among patients with HL-BC with either localized or regional/distant disease was also significantly increased (hazard ratio = 2.22, P = .04; and hazard ratio = 4.28, P = .02, respectively) compared with patients with BC-1. Although 10-year BC-CSS was similar for patients with HL-BC and BC-1 with regional/distant disease, it was inferior for patients with localized BC (82% v 88%, respectively; P = .002). CONCLUSION: Women with HL may survive a subsequent diagnosis of BC, only to experience significant excesses of death from other primary cancers and cardiac disease. Greater awareness of screening for cardiac disease and subsequent primary cancers in patients with HL-BC is warranted.
PURPOSE: The increased risk of breast cancer (BC) among women receiving chest radiotherapy for Hodgkin's lymphoma (HL) is well-established. However, there are no large population-based studies that describe overall survival (OS) and cause-specific survival (CSS) compared with women with first primary BC. METHODS: For 298 HL survivors who developed BC (HL-BC group) and 405,223 women with a first or only BC (BC-1 group), actuarial OS and CSS were compared, accounting for age, BC stage, hormone receptor status, sociodemographic status, radiation for HL, and other variables. All patients were derived from the population-based Surveillance, Epidemiology, and End Results program. RESULTS: OS among patients with HL-BC was significantly inferior that of to patients with BC-1: 15-year OS was 48% versus 69% (P < .0001) for localized BC, and 33% versus 43% (P < .0001) for regional/distant BC. Patients with HL-BC had a significantly increased seven-fold risk (P < .0001) of death from other cancers (ie, not HL or BC) compared with patients with BC-1. Mortality from heart disease among patients with HL-BC with either localized or regional/distant disease was also significantly increased (hazard ratio = 2.22, P = .04; and hazard ratio = 4.28, P = .02, respectively) compared with patients with BC-1. Although 10-year BC-CSS was similar for patients with HL-BC and BC-1 with regional/distant disease, it was inferior for patients with localized BC (82% v 88%, respectively; P = .002). CONCLUSION:Women with HL may survive a subsequent diagnosis of BC, only to experience significant excesses of death from other primary cancers and cardiac disease. Greater awareness of screening for cardiac disease and subsequent primary cancers in patients with HL-BC is warranted.
Authors: F E van Leeuwen; W J Klokman; M B Veer; A Hagenbeek; A D Krol; U A Vetter; M Schaapveld; P van Heerde; J M Burgers; R Somers; B M Aleman Journal: J Clin Oncol Date: 2000-02 Impact factor: 44.544
Authors: Annegien Broeks; Linde M Braaf; Lodewyk F A Wessels; Marc van de Vijver; Marie L De Bruin; Marilyn Stovall; Nicola S Russell; Flora E van Leeuwen; Laura J Van 't Veer Journal: Int J Radiat Oncol Biol Phys Date: 2010-02-01 Impact factor: 7.038
Authors: Giovanna Gagliardi; Louis S Constine; Vitali Moiseenko; Candace Correa; Lori J Pierce; Aaron M Allen; Lawrence B Marks Journal: Int J Radiat Oncol Biol Phys Date: 2010-03-01 Impact factor: 7.038
Authors: Mohamed A Alm El-Din; Kevin S Hughes; Dianne M Finkelstein; Keith A Betts; Torunn I Yock; Nancy J Tarbell; Alan C Aisenberg; Alphonse G Taghian Journal: Int J Radiat Oncol Biol Phys Date: 2008-06-04 Impact factor: 7.038
Authors: Marie L De Bruin; Judith Sparidans; Mars B van't Veer; Evert M Noordijk; Marieke W J Louwman; Josée M Zijlstra; Hendrik van den Berg; Nicola S Russell; Annegien Broeks; Margreet H A Baaijens; Berthe M P Aleman; Flora E van Leeuwen Journal: J Clin Oncol Date: 2009-08-10 Impact factor: 44.544
Authors: Mohamed A Alm El-Din; Kevin S Hughes; Rita A Raad; Saveli I Goldberg; Alan C Aisenberg; Andrzej Niemierko; Alphonse G Taghian Journal: Radiat Oncol Date: 2009-06-30 Impact factor: 3.481
Authors: Chaya S Moskowitz; Joanne F Chou; Joseph P Neglia; Ann H Partridge; Rebecca M Howell; Lisa R Diller; Danielle Novetsky Friedman; Dana Barnea; Lindsay M Morton; Lucie M Turcotte; Michael A Arnold; Wendy M Leisenring; Gregory T Armstrong; Leslie L Robison; Kevin C Oeffinger; Tara O Henderson Journal: J Clin Oncol Date: 2019-07-01 Impact factor: 44.544
Authors: Jennifer M Yeh; Kathryn P Lowry; Clyde B Schechter; Lisa R Diller; Oguzhan Alagoz; Gregory T Armstrong; John M Hampton; Wendy Leisenring; Qi Liu; Jeanne S Mandelblatt; Diana L Miglioretti; Chaya S Moskowitz; Kevin C Oeffinger; Amy Trentham-Dietz; Natasha K Stout Journal: Ann Intern Med Date: 2020-07-07 Impact factor: 25.391
Authors: Elena B Elkin; Michelle L Klem; Anne Marie Gonzales; Nicole M Ishill; David Hodgson; Andrea K Ng; Lawrence B Marks; Joanne Weidhaas; Gary M Freedman; Robert C Miller; Louis S Constine; Sten Myrehaug; Joachim Yahalom Journal: J Clin Oncol Date: 2011-05-16 Impact factor: 44.544
Authors: Matthew J Ehrhardt; Carrie R Howell; Karen Hale; Malek J Baassiri; Carol Rodriguez; Carmen L Wilson; Surekha S Joshi; Thomas C Lemond; Sheila Shope; Rebecca M Howell; Zhaoming Wang; Deokumar Srivastava; Daniel A Mulrooney; Jinghui Zhang; Leslie L Robison; Kirsten K Ness; Melissa M Hudson Journal: J Clin Oncol Date: 2019-05-10 Impact factor: 44.544
Authors: Lois B Travis; Wendy Demark Wahnefried; James M Allan; Marie E Wood; Andrea K Ng Journal: Nat Rev Clin Oncol Date: 2013-03-26 Impact factor: 66.675